Association of Neuromyelitis Optica With Severe and Intractable Pain. Qian P, Lancia S, Alvarez E, Klawiter EC, Cross AH, Naismith RT. Abstract OBJECTIVE To contrast differences in pain and treatment outcomes between neuromyelitis optica (NMO) and multiple sclerosis (MS)
Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica.
Background: Neuromyelitis optica (NMO) is a rare inflammatory disease. Average age at onset is 35 years
BACKGROUND: Interferon-β-1b (IFNβ-1b) has been used to prevent exacerbation of relapsing-remitting multiple sclerosis (RRMS) including optic-spinal multiple sclerosis (OSMS) in Japan. We encountered 2 patients with OSMS with unexpectedly severe exacerbation soon after the initiation of IFNβ-1b therapy. The experience urged us to retrospectively review the patients with RRMS who had been treated with IFNβ-1b to identify similar cases.